Safety policy

Harm-prevention principles

This site exists to provide educational context about peptide research compounds. Many of the compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. The following commitments govern every page of content.

Global disclaimer

This website is for educational and informational purposes only. No content on this site constitutes medical advice, diagnosis, treatment, or a recommendation to use any substance. Always consult a qualified, licensed healthcare provider before considering any peptide or compound. Many peptides described here are not FDA-approved for any human use, have not been demonstrated safe or effective in adequate human clinical trials, and may be illegal to purchase, possess, or administer in your jurisdiction.

What we will never publish

• Anecdotal, community-reported, or grey-market dosing for self-administered use.
• Administration protocols, injection-route instructions, or frequency schedules for self-use.
• Vial-concentration recipes or reconstitution instructions for self-use.
• Capsule fill-mass instructions or compounding recipes.
• Stacking recommendations or combination strategies.
• Sourcing guidance, including suppliers, vendors, or gray-market channels.
• Efficacy claims framed as established fact for unapproved compounds.
• Before/after anecdotes framed as evidence.
• Any language implying the site endorses use.

What we will publish (with strict citation requirements)

Peptide entries may display a "Doses reported in studies" section listing the amount, route, duration, and study population taken verbatim from a cited public source — a ClinicalTrials.gov protocol summary, a peer-reviewed published study, or an FDA-approved product label. Each record carries the source URL and citation, and each section carries a visible disclaimer that the content is historical study-protocol metadata, not a recommendation, not common-use guidance, and may not be safe or appropriate outside the cited context.

This section exists because a person trying to make a careful decision about a peptide that has been formally studied benefits from knowing what was actually administered in that study, under what supervision, to what population — and to whom the resulting safety/efficacy data therefore generalises. It does not exist to tell anyone what to take. We will not transcribe anecdotal forum posts, vendor pages, or social-media write-ups into that section regardless of how widely they are cited there.

Evidence quality labels

• Strong clinical evidence — FDA-approved or Phase 3 RCT in a peer-reviewed journal.
• Moderate clinical evidence — Phase 2 human trials with published results.
• Limited human data — Phase 1 pharmacokinetic data, small case series, or observational studies only.
• Preclinical only — Animal or in vitro studies only; no human clinical data.
• Insufficient evidence — No peer-reviewed studies; anecdotal reports only.

Per-compound disclaimer levels

• Standard — Cosmetic ingredients or FDA-approved drugs used outside their indication. The compound has a known identity and a baseline safety profile.
• Elevated — Not FDA-approved. Evidence is limited to animal models or small human studies. Safety in humans has not been established.
• Critical — No published human clinical trial data exists, regulatory action has restricted availability, or theoretical serious risks have not been ruled out.

Why we do not publish "grey-use" or anecdotal dosing

The distinction matters: we do show what doses were administered in a cited study or on an FDA-approved label (see "What we will publish" above). What we do not host is anecdotal or community-reported dose ranges, methods of administration, vial concentrations for injected use, or capsule masses for oral use — content sometimes requested on the rationale that people will use these compounds regardless, and that harm reduction calls for sharing the most-common practice rather than withholding it. We have considered that position carefully and have chosen not to host that content, for the following reasons.

• Anecdotal doses are not harm reduction. Community-reported ranges for unapproved peptides are not pharmacokinetic data. They typically lack denominator information (how many users had adverse events at the same dose), are biased toward self-reported success, and cannot account for individual differences in body composition, comorbidities, drug interactions, or compound purity.
• Reconstitution and capsule-mass figures normalise self-administration. Publishing a vial-concentration recipe or a capsule fill mass — even with disclaimers — communicates that there is a "right" amount for unsupervised use. For compounds without an FDA-approved label, there is no such amount we can responsibly publish.
• Compound identity and purity are not guaranteed outside the regulated supply chain. Grey-market vials and powders frequently differ from their labelled contents. A dose that is "commonly discussed" is meaningless if the substance in the vial is not what the label says it is.
• Liability is not the operative concern — patient safety is. We are not withholding this content to protect the project. We are withholding it because we cannot construct a presentation of it that we believe makes a reader safer than the alternatives below.

Safer alternatives we do support

• FDA-approved products with a published label. For peptides that have an approved indication (for example semaglutide, liraglutide, tirzepatide, tesamorelin), the manufacturer's prescribing information — accessible via the FDA drug databases and DailyMed — contains the dosing, administration, and safety information that has been reviewed by a regulator. That is the right place to read it, in the context of a prescriber's evaluation.
• Conversation prompts for a clinician. If you are considering a peptide, the most actionable preparation is a short, honest list of questions for a licensed physician or endocrinologist: what is the evidence for this compound in someone with my history; what are the realistic alternatives; what would you monitor; what would make you stop. We will surface those prompts; we will not substitute for them.
• Evidence-quality and disclaimer labels. Every entry on this site carries an evidence-quality label and a per-compound disclaimer level. "Preclinical only" and "Insufficient evidence" entries are not candidates for a dosing recommendation from anyone — including from anecdote.
• Emergency and poison-control resources. If you or someone you know has already taken a peptide and is experiencing concerning symptoms, contact emergency services. In the United States, Poison Control can be reached at 1-800-222-1222, 24 hours a day. Do not wait for a community thread to respond.

Clinician consultation

If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first. Research peptides are not substitutes for medical care.